Andrew Yip

Interventions to Improve Adherence to Clinical Guidelines for the Management and Follow-up of Pulmonary Nodules: A Systematic Review | CHEST® Journal Podcast - American College of Chest Physicians Justin Aunger, PhD, and Kay Por Yip, MBChB, PhD, discuss their research into interventions for improving adherence to clinical guidelines for the management and follow-up of pulmonary nodules.

Bite-sized audio version of our recently published systematic review. Do listen in on your work commute!

Listen here: hubs.la/Q03vHkK30

05.07.2025 14:44 — 👍 2    🔁 0    💬 0    📌 0

Job Advert

The Wythenshawe lung cancer/pleural team is looking for 3 senior clinical fellows to start later this year! Excellent exposure in lung cancer pathways, screening and procedural experiences! Currently in the post and happy to have a chat about it!

shorturl.at/HQ3Ok

28.05.2025 11:23 — 👍 0    🔁 0    💬 0    📌 0

Evaluation of Real-world Use of Pulmonary embolism Thrombolysis (ERUPT) IntroductionInternational guidelines recommend systemic thrombolysis for high-risk acute pulmonary embolism (PE). Significant uncertainties remain regarding thrombolysis in non high-risk PE and the use of reduced-dose thrombolysis. To address this, United Kingdom (UK) respiratory trainees led a multicentre UK-wide study assessing current practice. Our primary aim was to evaluate UK practice against the European Society of Cardiology (ESC) recommendations (specifically to utilise full-dose thrombolysis only in high-risk PE). Secondary outcomes included mortality and an analysis of clinical factors associated with administrating reduced-dose thrombolysis.MethodRetrospective multicentre observational study evaluating thrombolysis of acute PE from September 2021 to September 2022 in 26 centres across the UK.ResultsA total of 174 patients from 26 sites were included, with fibrinolytic dose recorded in 168 (96.6%) cases. After exclusion of 30 cases involving cardiac arrest, 26/138 patients (18.8%) received reduced-dose thrombolysis. Sixty-seven (39.9%) patients underwent thrombolysis for non high-risk PE. Factors associated with receiving reduced-dose thrombolysis included higher age (p= 0.005), higher Charlson Co-morbidity Index (CCI) (p=0.008) and higher serum lactate (p= 0.02).ConclusionPE thrombolysis in the UK deviates from international guidelines in a significant minority of cases; comprising the use of reduced-dose regimens and thrombolysis in non-high risk cases without haemodynamic deterioration. Prospective real-world studies, assessing clinical practise and outcomes following thrombolysis, should be conducted to understand the pragmatic application of evidence, and inform future guidelines.

First publication output from @inspireresp.bsky.social collaboration! A respiratory trainee research network to assess UK-wide practice for a common treatment dilemma: PE thrombolysis!

publications.ersnet.org/content/erjo...

01.05.2025 20:48 — 👍 0    🔁 0    💬 0    📌 0

Microsoft Forms

While you are reading this, please consider filling this form (forms.office.com/e/i9iRGQdaGg) to help better inform us the state of UK lung nodule follow-up!
#respsky #medsky

12.03.2025 19:52 — 👍 0    🔁 0    💬 0    📌 0

Interventions to improve adherence to clinical guidelines for the management and follow-up of pulmonary nodules: a systematic review There was significant variation in achieved follow-up rates across interventions; however, tracking systems appeared most effective in improving patient follow-up. Review limitations included high ris...

Very glad to have contributed to this meaningful systematic review. How do we prevent cracks in the pulmonary nodule follow-up pathway?
journal.chestnet.org/article/S001...
Thanks to Dr Justin Aunger for leading this and
Prof Alice Turner and Dr Mike Newnham for involving me in this

12.03.2025 19:52 — 👍 0    🔁 0    💬 1    📌 0

Already planning your calendar for 2️⃣ 0️⃣ 2️⃣ 5️⃣ ?

🐝 Why not visit us in Manchester & join us in our flagship #CancerImmunotherapy event. Programme now finalised & speakers confirmed 🤩!

🗓️ 2 days: 24 & 27 Jan 2025 (hybrid)

To register (discount code - IMMUNO10):
www.eventbrite.co.uk/e/the-cancer...

23.12.2024 19:53 — 👍 8    🔁 3    💬 0    📌 1

We are very much looking for the lung nodule management pathways and services throughout UK. Hopefully will inform on how services can be streamlined and improved. If you have a few minutes to spare, please fill this up!
#pulmsky

Link: forms.office.com/pages/respon...

12.12.2024 10:21 — 👍 3    🔁 1    💬 0    📌 0

Glad to have been back for #BTSWinter2024 in the day 1 morning spoken session earlier today - this time in lung cancer and frailty! Was hoping to project a more confident aura but failed 😅

27.11.2024 12:16 — 👍 3    🔁 0    💬 0    📌 0

Next in the pleural symposium with the results of the TACTIC trial by Dr Alexandra Dipper. No difference in hospital LOS and improvement in dyspnoea but more required further pleural interventions in the control arm. #BTSWinter2024

27.11.2024 12:06 — 👍 0    🔁 0    💬 0    📌 0

First work-related post!
Sitting at the pleural symposium at day 1 #BTSWinter2024. The REPEAT trial reported by Prof Eleanor Mishra looking at predictors of rate of pleural fluid reaccumulation in an MPE setting! Easy to use and clinically useful!

27.11.2024 11:37 — 👍 1    🔁 0    💬 0    📌 0

If you see this, post a concert pic you took.
First post on bsky - definitely a good first impression!

23.11.2024 21:42 — 👍 0    🔁 0    💬 0    📌 0